title: Wellbeing and public policy: Can New Zealand be a leading light for the ‘Wellbeing Approach’?

authors: Weijers, Dan M.

abstract: Delegates left the Third International Conference on Wellbeing and Public Policy with great expectations following three days of inspirational addresses by some of the world’s most prominent thinkers and policymakers. In this article we ask: what is required for a wellbeing approach to public expenditure to be successfully implemented and sustained?
The wellbeing approach arose out of concerns about whether the current suite of measures used by policymakers provides sufficient information on the full range of contributors to or components of the good life. Sometimes divided on what wellbeing is and how to measure it, proponents of the wellbeing approach agree that the ultimate goal of public policy should be to improve wellbeing for all citizens. In order for this wellbeing approach to be successful, we believe it must address three main challenges: measurement, representation and engagement. We must be clear about how wellbeing will be measured, whose wellbeing we will assess, and the extent to which all New Zealanders are represented in the conversations that will determine the first two issues.

text: Wellbeing and public policy: Can New Zealand be a leading light for the ‘Wellbeing Approach’? Delegates left the Third International Conference on Wellbeing and Public Policy with great expectations following three days of inspirational addresses by some of the world’s most prominent thinkers and policymakers. In this article we ask: what is required for a wellbeing approach to public expenditure to be successfully implemented and sustained?
The wellbeing approach arose out of concerns about whether the current suite of measures used by policymakers provides sufficient information on the full range of contributors to or components of the good life. Sometimes divided on what wellbeing is and how to measure it, proponents of the wellbeing approach agree that the ultimate goal of public policy should be to improve wellbeing for all citizens. In order for this wellbeing approach to be successful, we believe it must address three main challenges: measurement, representation and engagement. We must be clear about how wellbeing will be measured, whose wellbeing we will assess, and the extent to which all New Zealanders are represented in the conversations that will determine the first two issues.

year: 2018

title: Microwave aquametry of roasting coffee beans

authors: Kelly, Cameron Brian Desmond

abstract: We constructed a fluidsed-bed coffee roaster with a roast chamber that is also a microwave cavity in order to measure water content of roasting coffee. We identify factors involved in roasting that influence the data. We present a new approach to the problem of interpreting measurements that are noisy as a result of bean movement in the fluidised bed. Cleaned data permit aquametry throughout the roast. We seek the ideal point when an expert roaster would terminate the roast, but this measurement found no events or conditions that signal the ideal endpoint for a roast.

text: Microwave aquametry of roasting coffee beans We constructed a fluidsed-bed coffee roaster with a roast chamber that is also a microwave cavity in order to measure water content of roasting coffee. We identify factors involved in roasting that influence the data. We present a new approach to the problem of interpreting measurements that are noisy as a result of bean movement in the fluidised bed. Cleaned data permit aquametry throughout the roast. We seek the ideal point when an expert roaster would terminate the roast, but this measurement found no events or conditions that signal the ideal endpoint for a roast.

year: 2016

title: Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database

authors: Lawrenson, Ross

abstract: Background Small Cell Lung Cancer (SCLC) SCLC generally presents late and is treated with systemic anti-cancer treatment (SACT). Māori are over represented in Lung Cancer statistics but disparities between Māori and non-Māori in patterns of care and survival from SCLC have not been previously reported. 
Methods We used the custom-built SACT database collected by the Oncology Department at Waikato Hospital NZ, which recorded comprehensive lung cancer patient factors and SACT regimens from 2000 to 2021. We reported summary statistics to review the treatment by ethnicity, explored Kaplan Meier all-cause survival of patients, and estimated the unadjusted and adjusted odds ratios of surviving 12 months. 
Results 742 patients with SCLC were included in this study, with 43% identified as Māori. Approximately 75% of patients received SACT, and there was no difference in the uptake of SACT between Māori and non-Māori. The median survival for SCLC was 8.5 months. After adjustment, patients treated with carboplatin plus etoposide (with/without durvalumab) or cisplatin plus etoposide were 1.5 times or 4.9 times respectively more likely to survive 12 months than those without a SACT regimen.
Conclusion There was no significant evidence of disparities in patterns of care and outcomes between Māori and non-Māori with SCLC. Carboplatin/cisplatin in combination with etoposide remained the primary first line SACT regimen for patients with SCLC in this New Zealand cancer treatment centre.

text: Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database Background Small Cell Lung Cancer (SCLC) SCLC generally presents late and is treated with systemic anti-cancer treatment (SACT). Māori are over represented in Lung Cancer statistics but disparities between Māori and non-Māori in patterns of care and survival from SCLC have not been previously reported. 
Methods We used the custom-built SACT database collected by the Oncology Department at Waikato Hospital NZ, which recorded comprehensive lung cancer patient factors and SACT regimens from 2000 to 2021. We reported summary statistics to review the treatment by ethnicity, explored Kaplan Meier all-cause survival of patients, and estimated the unadjusted and adjusted odds ratios of surviving 12 months. 
Results 742 patients with SCLC were included in this study, with 43% identified as Māori. Approximately 75% of patients received SACT, and there was no difference in the uptake of SACT between Māori and non-Māori. The median survival for SCLC was 8.5 months. After adjustment, patients treated with carboplatin plus etoposide (with/without durvalumab) or cisplatin plus etoposide were 1.5 times or 4.9 times respectively more likely to survive 12 months than those without a SACT regimen.
Conclusion There was no significant evidence of disparities in patterns of care and outcomes between Māori and non-Māori with SCLC. Carboplatin/cisplatin in combination with etoposide remained the primary first line SACT regimen for patients with SCLC in this New Zealand cancer treatment centre.

year: 2023-02-10